Logo image of ASRT

ASSERTIO HOLDINGS INC (ASRT) Stock Fundamental Analysis

NASDAQ:ASRT - US04546C2052 - Common Stock

0.8052 USD
0 (0%)
Last: 9/11/2025, 8:00:00 PM
0.82 USD
+0.01 (+1.84%)
After Hours: 9/11/2025, 8:00:00 PM
Fundamental Rating

3

Overall ASRT gets a fundamental rating of 3 out of 10. We evaluated ASRT against 195 industry peers in the Pharmaceuticals industry. The financial health of ASRT is average, but there are quite some concerns on its profitability. ASRT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ASRT has reported negative net income.
ASRT had a positive operating cash flow in the past year.
In the past 5 years ASRT reported 4 times negative net income.
Of the past 5 years ASRT 4 years had a positive operating cash flow.
ASRT Yearly Net Income VS EBIT VS OCF VS FCFASRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -15.81%, ASRT is in the better half of the industry, outperforming 62.56% of the companies in the same industry.
ASRT has a Return On Equity (-46.40%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -15.81%
ROE -46.4%
ROIC N/A
ROA(3y)-32.33%
ROA(5y)-21.33%
ROE(3y)-69.93%
ROE(5y)-52.34%
ROIC(3y)N/A
ROIC(5y)N/A
ASRT Yearly ROA, ROE, ROICASRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 67.87%, ASRT is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
ASRT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ASRT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
ASRT Yearly Profit, Operating, Gross MarginsASRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

4

2. Health

2.1 Basic Checks

ASRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASRT has more shares outstanding
ASRT has more shares outstanding than it did 5 years ago.
ASRT has a worse debt/assets ratio than last year.
ASRT Yearly Shares OutstandingASRT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ASRT Yearly Total Debt VS Total AssetsASRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -2.96, we must say that ASRT is in the distress zone and has some risk of bankruptcy.
ASRT's Altman-Z score of -2.96 is in line compared to the rest of the industry. ASRT outperforms 45.64% of its industry peers.
ASRT has a debt to FCF ratio of 2.16. This is a good value and a sign of high solvency as ASRT would need 2.16 years to pay back of all of its debts.
ASRT has a better Debt to FCF ratio (2.16) than 93.33% of its industry peers.
A Debt/Equity ratio of 0.42 indicates that ASRT is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.42, ASRT perfoms like the industry average, outperforming 41.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF 2.16
Altman-Z -2.96
ROIC/WACCN/A
WACC9.92%
ASRT Yearly LT Debt VS Equity VS FCFASRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 1.59 indicates that ASRT should not have too much problems paying its short term obligations.
With a Current ratio value of 1.59, ASRT is not doing good in the industry: 66.15% of the companies in the same industry are doing better.
ASRT has a Quick Ratio of 1.34. This is a normal value and indicates that ASRT is financially healthy and should not expect problems in meeting its short term obligations.
ASRT has a Quick ratio of 1.34. This is in the lower half of the industry: ASRT underperforms 65.64% of its industry peers.
Industry RankSector Rank
Current Ratio 1.59
Quick Ratio 1.34
ASRT Yearly Current Assets VS Current LiabilitesASRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 69.83% over the past year.
The Revenue for ASRT has decreased by -11.40% in the past year. This is quite bad
ASRT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.45% yearly.
EPS 1Y (TTM)69.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325%
Revenue 1Y (TTM)-11.4%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%-6.12%

3.2 Future

Based on estimates for the next years, ASRT will show a very strong growth in Earnings Per Share. The EPS will grow by 35.53% on average per year.
Based on estimates for the next years, ASRT will show a small growth in Revenue. The Revenue will grow by 4.54% on average per year.
EPS Next Y-81.83%
EPS Next 2Y9.62%
EPS Next 3Y32.2%
EPS Next 5Y35.53%
Revenue Next Year-7.97%
Revenue Next 2Y-1.3%
Revenue Next 3Y2.76%
Revenue Next 5Y4.54%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ASRT Yearly Revenue VS EstimatesASRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
ASRT Yearly EPS VS EstimatesASRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ASRT. In the last year negative earnings were reported.
Also next year ASRT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASRT Price Earnings VS Forward Price EarningsASRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ASRT is valued cheaper than 98.46% of the companies in the same industry.
Industry RankSector Rank
P/FCF 4.29
EV/EBITDA N/A
ASRT Per share dataASRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

ASRT's earnings are expected to grow with 32.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.62%
EPS Next 3Y32.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ASRT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASSERTIO HOLDINGS INC

NASDAQ:ASRT (9/11/2025, 8:00:00 PM)

After market: 0.82 +0.01 (+1.84%)

0.8052

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners27.02%
Inst Owner Change-3.58%
Ins Owners1.38%
Ins Owner Change3.41%
Market Cap77.49M
Analysts82
Price Target2.81 (248.98%)
Short Float %5.16%
Short Ratio19.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-42.33%
Min EPS beat(2)-119.3%
Max EPS beat(2)34.64%
EPS beat(4)2
Avg EPS beat(4)-48.42%
Min EPS beat(4)-145.1%
Max EPS beat(4)36.06%
EPS beat(8)2
Avg EPS beat(8)-484.65%
EPS beat(12)4
Avg EPS beat(12)-320.69%
EPS beat(16)7
Avg EPS beat(16)-209.36%
Revenue beat(2)1
Avg Revenue beat(2)-1.4%
Min Revenue beat(2)-5.64%
Max Revenue beat(2)2.84%
Revenue beat(4)2
Avg Revenue beat(4)1.6%
Min Revenue beat(4)-5.64%
Max Revenue beat(4)10.04%
Revenue beat(8)4
Avg Revenue beat(8)-2.43%
Revenue beat(12)8
Avg Revenue beat(12)0.26%
Revenue beat(16)12
Avg Revenue beat(16)2.45%
PT rev (1m)-1.79%
PT rev (3m)-1.79%
EPS NQ rev (1m)-25%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-29.75%
EPS NY rev (3m)-86.36%
Revenue NQ rev (1m)-7.87%
Revenue NQ rev (3m)-16.66%
Revenue NY rev (1m)-1.72%
Revenue NY rev (3m)-1.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.66
P/FCF 4.29
P/OCF 4.29
P/B 0.83
P/tB 2.48
EV/EBITDA N/A
EPS(TTM)-0.35
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)0.19
FCFY23.31%
OCF(TTM)0.19
OCFY23.31%
SpS1.22
BVpS0.97
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.81%
ROE -46.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.87%
FCFM 15.43%
ROA(3y)-32.33%
ROA(5y)-21.33%
ROE(3y)-69.93%
ROE(5y)-52.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF 2.16
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.59
Quick Ratio 1.34
Altman-Z -2.96
F-Score3
WACC9.92%
ROIC/WACCN/A
Cap/Depr(3y)16.81%
Cap/Depr(5y)10.15%
Cap/Sales(3y)3.56%
Cap/Sales(5y)2.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325%
EPS Next Y-81.83%
EPS Next 2Y9.62%
EPS Next 3Y32.2%
EPS Next 5Y35.53%
Revenue 1Y (TTM)-11.4%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%-6.12%
Revenue Next Year-7.97%
Revenue Next 2Y-1.3%
Revenue Next 3Y2.76%
Revenue Next 5Y4.54%
EBIT growth 1Y-84.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year169.51%
EBIT Next 3Y65.52%
EBIT Next 5Y43.58%
FCF growth 1Y-70.67%
FCF growth 3Y69.74%
FCF growth 5Y-21.57%
OCF growth 1Y-76.84%
OCF growth 3Y68.7%
OCF growth 5Y-21.83%